The clinical antiprotozoal drug halofuginone promotes weight loss by elevating GDF15 and FGF21

knockout mice, we show that both hormones are necessary to elicit anti-obesity changes. Together, our study reports the beneficial metabolic effects of halofuginone and underscores its utility in treating obesity and its associated metabolic complications, which merits clinical assessment.